{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:08:02Z","timestamp":1791673682847,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T00:00:00Z","timestamp":1656806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaci.2022.05.023","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T07:07:37Z","timestamp":1667459257000},"page":"999-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Comprehensive overview of autoantibody isotype and subclass distribution"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7577-2994","authenticated-orcid":false,"given":"Mikhail","family":"Volkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J.","family":"van der Kooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth E.M.","family":"Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Sciarrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Titulaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E.M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.M.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"van Schie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.05.023_bib1","series-title":"Measuring immunity","first-page":"158","article-title":"Chapter 12\u2014Immunoglobulin titers and immunoglobulin subtypes","author":"Petar","year":"2005"},{"key":"10.1016\/j.jaci.2022.05.023_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0009-8981(75)90257-0","article-title":"Serum immunoglobulins in healthy children and adults levels of the five classes, expressed in international units per millilitre","volume":"65","author":"Zegers","year":"1975","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaci.2022.05.023_bib3","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/eji.201646547","article-title":"The enigmatic function of IgD: some answers at last","volume":"48","author":"Gutzeit","year":"2018","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.coi.2009.05.010","article-title":"Follicular helper T cells as cognate regulators of B cell immunity","volume":"21","author":"McHeyzer-Williams","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib6","doi-asserted-by":"crossref","first-page":"J276","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"Chen","year":"2010","journal-title":"J Autoimmunity"},{"key":"10.1016\/j.jaci.2022.05.023_bib7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib8","series-title":"Antibody Fc","first-page":"131","article-title":"Chapter 7\u2014Structural recognition of immunoglobulins by Fcg receptors","author":"Sun","year":"2014"},{"key":"10.1016\/j.jaci.2022.05.023_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.1957.02980130015004","article-title":"Chronic thyroiditis and autoimmunization","volume":"164","author":"Witebsky","year":"1957","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jaci.2022.05.023_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.64.8.1121","article-title":"Classification of myasthenia gravis based on autoantibody status","volume":"64","author":"Suzuki","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaci.2022.05.023_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.05.023_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/cen3.12590","article-title":"Treatment of chronic inflammatory demyelinating polyradiculoneuropathy patients with antibodies against paranodal proteins","volume":"11","author":"Iijima","year":"2020","journal-title":"Clin Exp Neuroimmunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/clin.1993.1008","article-title":"Subclasses of immunoglobulins and autoantibodies in autoimmune diseases","volume":"66","author":"Outschoorn","year":"1993","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jaci.2022.05.023_bib15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102646","article-title":"Update on IgG4-mediated autoimmune diseases: new insights and new family members","volume":"19","author":"Koneczny","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2022.05.023_bib17","first-page":"278","article-title":"Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6","volume":"84","author":"Kawano","year":"1995","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2022.05.023_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10875-012-9825-6","article-title":"Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis","volume":"33","author":"Sui","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib20","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1016\/S0264-410X(03)00336-0","article-title":"Transfer of antibody via mother\u2019s milk","volume":"21","author":"Van de Perre","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jaci.2022.05.023_bib21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.jaci.2022.05.023_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.jaci.2022.05.023_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.jaci.2022.05.023_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force\u2014second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jaci.2022.05.023_bib25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jmb.2013.10.039","article-title":"Structural determinants of unique properties of human IgG4-Fc","volume":"426","author":"Davies","year":"2014","journal-title":"J Mol Biol"},{"key":"10.1016\/j.jaci.2022.05.023_bib26","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Van Der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jaci.2022.05.023_bib27","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.4049\/jimmunol.163.5.2944","article-title":"Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation","volume":"163","author":"van Neerven","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","article-title":"Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fcgamma receptor activation pathways","volume":"9","author":"Lilienthal","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12026-016-8790-1","article-title":"IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study","volume":"64","author":"Yang","year":"2016","journal-title":"Immunol Res"},{"key":"10.1016\/j.jaci.2022.05.023_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1\u2013associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jaci.2022.05.023_bib31","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jaci.2022.05.023_bib32","doi-asserted-by":"crossref","first-page":"9620","DOI":"10.1073\/pnas.1512561112","article-title":"High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome","volume":"112","author":"Casina","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib33","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1172\/JCI64413","article-title":"Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface","volume":"122","author":"Di Zenzo","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jaci.2022.05.023_bib34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/ene.12758","article-title":"The expanding field of IgG4-mediated neurological autoimmune disorders","volume":"22","author":"Huijbers","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jaci.2022.05.023_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2018.00097","article-title":"A new classification system for IgG4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0036-1584322","article-title":"The immunobiology of immunoglobulin G4","volume":"36","author":"Lighaam","year":"2016","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jaci.2022.05.023_bib37","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1073\/pnas.90.8.3730","article-title":"Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells","volume":"90","author":"Punnonen","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib38","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.4049\/jimmunol.172.5.3252","article-title":"Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity","volume":"172","author":"Nouri-Aria","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.05.023_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.4049\/jimmunol.130.2.722","article-title":"Serologic aspects of IgG4 antibodies, I: prolonged immunization results in an IgG4-restricted response","volume":"130","author":"Aalberse","year":"1983","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib41","first-page":"152","article-title":"Diagnostic reliability considerations of specific IgE determination","volume":"6","author":"Sanz","year":"1996","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/intimm\/dxg036","article-title":"Evidence of allosteric conformational changes in the antibody constant region upon antigen binding","volume":"15","author":"Oda","year":"2003","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib43","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1038\/s41598-020-61455-8","article-title":"Cell-bound IgE and plasma IgE as a combined clinical diagnostic indicator for allergic patients","volume":"10","author":"Qiu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2022.05.023_bib44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2022.05.023_bib45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2018.00689","article-title":"Immunoglobulin E-mediated autoimmunity","volume":"9","author":"Maurer","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib47","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3389\/fimmu.2019.01918","article-title":"Learning from success and failure: biologics for non-approved skin diseases","volume":"10","author":"Speeckaert","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/08916934.2017.1280670","article-title":"Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses","volume":"50","author":"Ettinger","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaci.2022.05.023_bib49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11882-016-0621-x","article-title":"The developmental history of IgE and IgG4 antibodies in relation to atopy, eosinophilic esophagitis, and the modified TH2 response","volume":"16","author":"Aalberse","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2022.05.023_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/1744-9987.12474","article-title":"Therapeutic apheresis in hematologic, autoimmune and dermatologic diseases with immunologic origin","volume":"20","author":"Bambauer","year":"2016","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jaci.2022.05.023_bib52","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.semnephrol.2017.05.020","article-title":"Immunoadsorption in autoimmune diseases affecting the kidney","volume":"37","author":"Stummvoll","year":"2017","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jaci.2022.05.023_bib53","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1038\/s41598-020-64744-4","article-title":"Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness","volume":"10","author":"Klingele","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2022.05.023_bib54","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the Seventh Special Issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jaci.2022.05.023_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ebiom.2017.02.007","article-title":"Extracorporeal IgE immunoadsorption in allergic asthma: safety and efficacy","volume":"17","author":"Lupinek","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaci.2022.05.023_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2007.11.030","article-title":"B cell\u2013directed therapies for autoimmune disease and correlates of disease response and relapse","volume":"121","author":"Levesque","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib57","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib59","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib60","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.37850","article-title":"Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis","volume":"65","author":"St Clair","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.05.023_bib61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.05.023_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2022.05.023_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.13015","article-title":"On the road to eliminating long-lived plasma cells\u2014\u201care we there yet?\u201d","volume":"303","author":"Markmann","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2022.05.023_bib64","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.05.023_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2022.05.023_bib66","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2022.05.023_bib67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib68","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2021.09.020","article-title":"Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome","volume":"100","author":"Enghard","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaci.2022.05.023_bib69","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.05.023_bib70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib72","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib73","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/WNL.45.8.1570","article-title":"Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis","volume":"45","author":"Van Schaik","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2022.05.023_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12902-019-0363-6","article-title":"Comparison of five TSH-receptor antibody assays in Graves\u2019 disease: results from an observational pilot study","volume":"19","author":"Struja","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jaci.2022.05.023_bib75","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","article-title":"Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays","volume":"76","author":"Damoiseaux","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.05.023_bib76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2014.11.001","article-title":"Improving the detection of IgM antibodies against glycolipids complexes of GM1 and Galactocerebroside in multifocal motor neuropathy using glycoarray and ELISA assays","volume":"278","author":"Delmont","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib77","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458512443917","article-title":"Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica","volume":"18","author":"Isobe","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaci.2022.05.023_bib78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","article-title":"A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris","volume":"70","author":"Kamiya","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib79","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/ijd.12768","article-title":"Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity","volume":"54","author":"Barnadas","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib80","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib81","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1468-3083.2007.02254.x","article-title":"Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity","volume":"21","author":"Daneshpazhooh","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2022.05.023_bib82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2340\/00015555-1961","article-title":"Correlation of conventional and conformational anti-desmoglein antibodies with phenotypes and disease activities in patients with pemphigus vulgaris","volume":"95","author":"Li","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2022.05.023_bib83","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1468-3083.2011.04294.x","article-title":"Utility of desmoglein ELISA in the clinical correlation and disease monitoring of pemphigus vulgaris","volume":"26","author":"Anand","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2022.05.023_bib84","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jop.12913","article-title":"Pemphigus vulgaris disease activity: the role of antibodies to desmogleins and their isotype","volume":"48","author":"Yeoh","year":"2019","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jaci.2022.05.023_bib85","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1196\/annals.1313.019","article-title":"Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis","volume":"1050","author":"Sinico","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib86","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10067-019-04693-0","volume":"38","author":"Fijolek","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib87","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005096","article-title":"Diagnosing ANCA-associated vasculitis in ANCA positive patients: a retrospective analysis on the role of clinical symptoms and the ANCA titre","volume":"95","author":"Houben","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2022.05.023_bib88","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2022.05.023_bib89","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/ard.2008.094714","article-title":"Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides","volume":"68","author":"Terrier","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.05.023_bib90","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jfma.2019.05.004","article-title":"High anti-neutrophil cytoplasmic antibody titers are associated with the requirement of permanent dialysis in patients with myeloperoxidase-ANCA-associated vasculitis","volume":"118","author":"Yen","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jaci.2022.05.023_bib91","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458511424590","article-title":"Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jaci.2022.05.023_bib92","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.65.7.913","article-title":"Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis","volume":"65","author":"Waters","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jaci.2022.05.023_bib93","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jaci.2022.05.023_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116671","article-title":"Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD)","volume":"410","author":"Akaishi","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jaci.2022.05.023_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577168","article-title":"Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders","volume":"340","author":"Akaishi","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib96","doi-asserted-by":"crossref","first-page":"J223","DOI":"10.1016\/j.jaut.2011.11.018","article-title":"Neonatal autoimmune diseases: a critical review","volume":"38","author":"Chang","year":"2012","journal-title":"J Autoimmunity"},{"key":"10.1016\/j.jaci.2022.05.023_bib97","first-page":"37","article-title":"Immunoglobulins: structure and function","volume":"4","author":"Frazer","year":"1999","journal-title":"Fundamental Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib98","article-title":"Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection","volume":"7","author":"Bohannon","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2022.05.023_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0166-0934(80)90002-6","article-title":"The interference of IgM rheumatoid factor in enzyme-linked immunosorbent assays of rubella IgM and IgG antibodies","volume":"1","author":"Vejtorp","year":"1980","journal-title":"J Virol Methods"},{"key":"10.1016\/j.jaci.2022.05.023_bib100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200405000-00013","article-title":"Rheumatoid factor revisited","volume":"16","author":"Dorner","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2022.05.023_bib102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02030749","article-title":"A study of IgM rheumatoid factors in a middle-aged population of Northern Norway","volume":"3","author":"Gran","year":"1984","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2022.05.023_bib103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/labmed\/23.4.259","article-title":"Enzyme-based methods for IgM serology: standard indirect ELISA vs antibody-capture ELISA","volume":"23","author":"Wilson","year":"1992","journal-title":"Lab Med"},{"key":"10.1016\/j.jaci.2022.05.023_bib104","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.4049\/jimmunol.2000767","article-title":"Development of a SARS-CoV-2 total antibody assay and the dynamics of antibody response over time in hospitalized and nonhospitalized patients with COVID-19","volume":"205","author":"Vogelzang","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.05.023_bib106","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922008454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922008454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:39:46Z","timestamp":1758793186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922008454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0091674922008454"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.05.023","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive overview of autoantibody isotype and subclass distribution","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}